Karsten Milek

Learn More
OBJECTIVE Hypoglycemia causes recurrent morbidity in patients with type 2 diabetes. This study evaluated if exenatide twice daily (BID) was noninferior to premixed insulin aspart 70/30 BID (PIA) for glycemic control and associated with less hypoglycemia. RESEARCH DESIGN AND METHODS In this open-label study, metformin-treated adults with type 2 diabetes(More)
BACKGROUND A new IOL implantation technique introduced in Germany since December 1995 is presented--the one-piece-plate-haptic silicone lens implantable with the Passport system. METHOD From January to September 1996 in 291 patients after 3.2 mm clear cornea incision, capsulorhexis, phacoemulsification and implantation of an one-piece silicone posterior(More)
RESULTS—Exenatide BID (n = 181) was noninferior to PIA (n = 173) for A1C control (least squares [LS] mean change21.0 vs.21.14%; difference [95% CI] 0.14 [20.003 to 0.291]) and associated with a lower risk for hypoglycemia (8.0 vs. 20.5%, P , 0.05). LS mean weight decreased by 4.1 kg and increased by 1.0 kg with PIA (P , 0.001). A total of 39.2 vs. 20.8% of(More)
BACKGROUND Insulin degludec (IDeg) is a basal insulin with a stable, flat action profile and an even distribution of the blood glucose lowering effect over 24 hou rs. The terminal half-life of IDeg is about 25 hours, which reflects a mean prolongation by factor 2 compared to Insulin glargin (lGlar).This may enable for a more flexible daytime dosing versus(More)
  • 1